Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Kopetz

Showing results (1-10 of 456) with videos related to

Pageof 46
Sort By:
Clinical Advances in Hematology & Oncology : H&O|June 1, 2018
How should BRAF V600E-mutated colorectal cancer be treated?Scott Kopetz
Clinical Advances in Hematology & Oncology : H&O|January 6, 2021
Circulating tumor DNA as a marker of minimal residual disease in colorectal cancerScott Kopetz
Clinical Advances in Hematology & Oncology : H&O|June 12, 2026
Targeting BRAF V600E mutations in metastatic colorectal cancerScott Kopetz
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
"Right drug for the right patient": hurdles and the path forward in colorectal cancerScott Kopetz
Clinical Advances in Hematology & Oncology : H&O|March 7, 2008
Novel targets for systemic therapy of colorectal cancerScott Kopetz
Gastrointestinal Cancer Research : GCR|April 11, 2009
Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinicScott Kopetz
Nature Reviews. Gastroenterology & Hepatology|December 22, 2018
New therapies and insights into the changing landscape of colorectal cancerScott Kopetz
Colorectal Cancer|January 20, 2015
Challenges and strategies for identifying biomarkers for colorectal cancerBruno Conte, Scott Kopetz
F1000Prime Reports|April 16, 2013
BRAF inhibitors in clinical oncologyVan Morris, Scott Kopetz
Current Oncology Reports|March 5, 2011
Predictive and prognostic markers in colorectal cancerBen George, Scott Kopetz
Pageof 46

Showing results (1-10 of 456) with videos related to

Sort By:
Pageof 46
Clinical Advances in Hematology & Oncology : H&O|June 1, 2018
How should BRAF V600E-mutated colorectal cancer be treated?Scott Kopetz
Clinical Advances in Hematology & Oncology : H&O|January 6, 2021
Circulating tumor DNA as a marker of minimal residual disease in colorectal cancerScott Kopetz
Clinical Advances in Hematology & Oncology : H&O|June 12, 2026
Targeting BRAF V600E mutations in metastatic colorectal cancerScott Kopetz
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
"Right drug for the right patient": hurdles and the path forward in colorectal cancerScott Kopetz
Clinical Advances in Hematology & Oncology : H&O|March 7, 2008
Novel targets for systemic therapy of colorectal cancerScott Kopetz
Gastrointestinal Cancer Research : GCR|April 11, 2009
Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinicScott Kopetz
Nature Reviews. Gastroenterology & Hepatology|December 22, 2018
New therapies and insights into the changing landscape of colorectal cancerScott Kopetz
Colorectal Cancer|January 20, 2015
Challenges and strategies for identifying biomarkers for colorectal cancerBruno Conte, Scott Kopetz
F1000Prime Reports|April 16, 2013
BRAF inhibitors in clinical oncologyVan Morris, Scott Kopetz
Current Oncology Reports|March 5, 2011
Predictive and prognostic markers in colorectal cancerBen George, Scott Kopetz
Pageof 46